CTAD 2024 | The ALTITUDE-AD trial: targeting soluble amyloid-β oligomers with sabirnetug in AD

Todd Feaster, PsyD, Acumen Pharmaceuticals, Carmel, IN, speaks about the Phase II ALTITUDE-AD trial, investigating sabirnetug, a drug that targets soluble amyloid-β oligomers, in Alzheimer’s disease (AD). The trial is currently enrolling and aims to begin data collection next year. This interview took place at the 17th Clinical Trials on Alzheimer’s Disease (CTAD) congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.